Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DBV Technologies (DBVT) Non-Current Debt (2014 - 2020)

DBV Technologies (DBVT) reported Non-Current Debt of $805167.4 for Q2 2020, down 28.56% year-over-year from $1.1 million in Q3 2019, and up 0.89% on a QoQ basis from $798066.0 in Q4 2019.

DBV Technologies (DBVT) has 7 years of Non-Current Debt data on file, last reported at $805167.4 in Q2 2020.

  • Quarterly Non-Current Debt fell 28.56% year-over-year to $805167.4 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $805167.4 (down 28.56% YoY) and the FY2019 annual result came in at $798066.0, down 45.29% from the prior year.
  • Non-Current Debt climbed to $805167.4 in Q2 2020 per DBVT's latest filing, from $798066.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $4.9 million in Q2 2016 and bottomed at $798066.0 in Q4 2019.
  • The 5-year median for Non-Current Debt is $1.7 million (2018), against an average of $2.3 million.
  • The widest annual swing landed in 2016, when Non-Current Debt dropped 5.32%; it then tumbled 54.98% in 2018.
  • Tracing DBVT's Non-Current Debt over 5 years: stood at $4.4 million in 2016, then slumped by 50.85% to $2.1 million in 2017, then slumped by 32.12% to $1.5 million in 2018, then plunged by 45.29% to $798066.0 in 2019, then increased by 0.89% to $805167.4 in 2020.
  • Per Business Quant, the three latest DBVT Non-Current Debt figures stand at $805167.4 (Q2 2020), $798066.0 (Q4 2019), and $959173.3 (Q3 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 805,167.35
Jun 30, 2020 805,167.35
Dec 31, 2019 798,066.01
Dec 31, 2019 798,066.01
Sep 30, 2019 959,173.29
Sep 30, 2019 959,173.29
Jun 30, 2019 1.13 Mn
Jun 30, 2019 1.13 Mn
Dec 31, 2018 1.46 Mn
Dec 31, 2018 1.46 Mn
Jun 30, 2018 1.85 Mn
Jun 30, 2018 1.85 Mn
Dec 31, 2017 2.15 Mn
Dec 31, 2017 2.15 Mn
Jun 30, 2017 4.11 Mn
Jun 30, 2017 4.11 Mn
Dec 31, 2016 4.37 Mn
Dec 31, 2016 4.37 Mn
Jun 30, 2016 4.94 Mn
Jun 30, 2016 4.94 Mn
Dec 31, 2015 5.14 Mn
Dec 31, 2015 5.14 Mn
Jun 30, 2015 5.22 Mn
Jun 30, 2015 5.22 Mn
Dec 31, 2014 4.86 Mn
Dec 31, 2014 4.86 Mn